Zhao X, Jagadeesh D, Bodo J, Durkin L, Lindner D, Ondrejka S
EJHaem. 2025; 6(1):e1080.
PMID: 39877932
PMC: 11773159.
DOI: 10.1002/jha2.1080.
Kodali S, Sands C, Guo L, Huang Y, Di Stefano B
Nat Rev Immunol. 2025; .
PMID: 39875604
DOI: 10.1038/s41577-025-01130-z.
Dimitri A, Baxter A, Chen G, Hopkins C, Rouin G, Huang H
Sci Adv. 2024; 10(46):eadp9371.
PMID: 39536093
PMC: 11559603.
DOI: 10.1126/sciadv.adp9371.
Locher B, Lowe P, Christen F, Damm F
Methods Mol Biol. 2024; 2865:449-474.
PMID: 39424737
DOI: 10.1007/978-1-0716-4188-0_20.
Davletgildeeva A, Kuznetsov N
Biomolecules. 2024; 14(9).
PMID: 39334883
PMC: 11430729.
DOI: 10.3390/biom14091117.
Perturbing TET2 condensation promotes aberrant genome-wide DNA methylation and curtails leukaemia cell growth.
Guo L, Hong T, Lee Y, Hu X, Pan G, Zhao R
Nat Cell Biol. 2024; 26(12):2154-2167.
PMID: 39251719
DOI: 10.1038/s41556-024-01496-7.
T-cell receptor architecture and clonal tiding provide insight into the transformation trajectory of peripheral T-cell lymphomas.
Willscher E, Schultheiss C, Paschold L, Lea Schumann F, Schmidt-Barbo P, Thiele B
Haematologica. 2024; 110(2):457-469.
PMID: 39219501
PMC: 11788643.
DOI: 10.3324/haematol.2024.285395.
Translation of Epigenetics in Cell-Free DNA Liquid Biopsy Technology and Precision Oncology.
Tan W, Nagabhyrava S, Ang-Olson O, Das P, Ladel L, Sailo B
Curr Issues Mol Biol. 2024; 46(7):6533-6565.
PMID: 39057032
PMC: 11276574.
DOI: 10.3390/cimb46070390.
Phase 2 trial of the farnesyltransferase inhibitor tipifarnib for relapsed/refractory peripheral T-cell lymphoma.
Witzig T, Sokol L, Kim W, de la Cruz Vicente F, Garcia-Sancho A, Advani R
Blood Adv. 2024; 8(17):4581-4592.
PMID: 38991123
PMC: 11401221.
DOI: 10.1182/bloodadvances.2024012806.
A combination of 5-azacytidine and nivolumab is a potentially effective rescue therapy in relapsed/refractory AITL.
Ricard L, Cervera P, Stocker N, Corre E, Van de Wyngaert Z, Banet A
Front Immunol. 2024; 15:1410638.
PMID: 38983865
PMC: 11231067.
DOI: 10.3389/fimmu.2024.1410638.
DNA methylation in human diseases.
Younesian S, Mohammadi M, Younesian O, Momeny M, Ghaffari S, Bashash D
Heliyon. 2024; 10(11):e32366.
PMID: 38933971
PMC: 11200359.
DOI: 10.1016/j.heliyon.2024.e32366.
Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial.
Horwitz S, Nirmal A, Rahman J, Xu R, Drill E, Galasso N
Nat Med. 2024; 30(9):2517-2527.
PMID: 38886623
PMC: 11862811.
DOI: 10.1038/s41591-024-03076-6.
Chidamide in combination with azacitidine for an elderly patient with peripheral T cell lymphoma‑not otherwise specified: A case report.
Liu H, Xue F, Zhou R, Tian H, Mao J, Wu T
Oncol Lett. 2024; 28(2):341.
PMID: 38855506
PMC: 11157661.
DOI: 10.3892/ol.2024.14474.
Novel clinical risk stratification and treatment strategies in relapsed/refractory peripheral T-cell lymphoma.
Chang E, Tan Y, Chan J
J Hematol Oncol. 2024; 17(1):38.
PMID: 38824603
PMC: 11144347.
DOI: 10.1186/s13045-024-01560-7.
Targeting DNMT3A-mediated oxidative phosphorylation to overcome ibrutinib resistance in mantle cell lymphoma.
Hoang N, Liu Y, Bates P, Heaton A, Lopez A, Liu P
Cell Rep Med. 2024; 5(4):101484.
PMID: 38554704
PMC: 11031386.
DOI: 10.1016/j.xcrm.2024.101484.
The dark side of stemness - the role of hematopoietic stem cells in development of blood malignancies.
Filipek-Gorzala J, Kwiecinska P, Szade A, Szade K
Front Oncol. 2024; 14:1308709.
PMID: 38440231
PMC: 10910019.
DOI: 10.3389/fonc.2024.1308709.
Genomic and transcriptomic profiling of peripheral T cell lymphoma reveals distinct molecular and microenvironment subtypes.
Huang Y, Qiu Y, Zhang Q, Cai M, Yu H, Zhang J
Cell Rep Med. 2024; 5(2):101416.
PMID: 38350451
PMC: 10897627.
DOI: 10.1016/j.xcrm.2024.101416.
Common clonal origin of three distinct hematopoietic neoplasms in a single patient: B-cell lymphoma, T-cell lymphoma, and polycythemia vera.
Nkosi D, Allbee A, Rothberg P, Friedberg J, Evans A
Cold Spring Harb Mol Case Stud. 2024; 9(4).
PMID: 38199781
PMC: 10815289.
DOI: 10.1101/mcs.a006313.
Transgenerational Epigenetic DNA Methylation Editing and Human Disease.
Tompkins J
Biomolecules. 2023; 13(12).
PMID: 38136557
PMC: 10742326.
DOI: 10.3390/biom13121684.
Tumor heterogeneity and immune-evasive T follicular cell lymphoma phenotypes at single-cell resolution.
Suma S, Suehara Y, Fujisawa M, Abe Y, Hattori K, Makishima K
Leukemia. 2023; 38(2):340-350.
PMID: 38012392
PMC: 10844096.
DOI: 10.1038/s41375-023-02093-7.
